Skip to content

ArriVent BioPharma

US · AVBP #3057 by market cap Listed 2024
10.52 -0.74 -6.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $29
    Market Newswire · 2026/10/20
  • Rating change
    Clear Street Maintains ArriVent BioPharma(AVBP.US) With Buy Rating
    Market Newswire · 2026/10/26
  • Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $23
    Market Newswire · 2026/11/10
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/9/15
  • Rating change
    Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $21
    Market Newswire · 2026/10/27
  • Rating change
    H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $27
    Market Newswire · 2026/10/8
  • Rating change
    ArriVent BioPharma, Inc. (AVBP) Gets a Buy From Guggenheim
    TipRanks · 2026/9/15
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/9/15
  • Rating change
    Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $25
    Market Newswire · 2026/10/27
  • Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/11/12
  • Rating change
    Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating
    Market Newswire · 2026/9/16
  • Rating change
    Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $30
    Market Newswire · 2026/10/27
  • Rating change
    BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $29
    Market Newswire · 2026/10/7
  • BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/11/10
  • Rating change
    Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $20
    Market Newswire · 2026/10/7
  • H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $27
    Market Newswire · 2026/10/28
  • Rating change
    Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
    TipRanks · 2026/10/7
  • Rating change
    Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB), Nuvation Bio (NUVB) and ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/9/15
  • A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $22 to $27
    Market Newswire · 2026/11/11
  • Rating change
    A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $45
    Market Newswire · 2026/9/15
  • Rating change
    H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47
    Market Newswire · 2026/8/17
  • Rating change
    A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50
    Market Newswire · 2026/8/14
  • Rating change
    Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40
    Market Newswire · 2026/8/15
  • BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/10/27
  • Rating change
    Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Alterity Therapeutics (ATHE)
    TipRanks · 2026/8/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ArriVent BioPharma discussion 0 comments

Add a comment